See the DrugPatentWatch profile for mili
The price of Trili is not publicly disclosed by its manufacturer, Takeda Pharmaceutical Company [1]. This information is typically proprietary and not shared openly.
What is Trili used for?
Trili, also known by its generic name, trabectedin, is a prescription medication used to treat certain types of cancer. Specifically, it is indicated for the treatment of unresectable or metastatic liposarcoma and leiomyosarcoma in patients who have received prior anthracycline treatment [1].
How does trabectedin work?
Trabectedin is a complex marine-derived compound that works by binding to DNA and interfering with cellular processes critical for cancer cell growth and survival. It affects multiple DNA repair pathways and transcription, ultimately leading to programmed cell death (apoptosis) in tumor cells [1].
Are there clinical trials for Trili?
Clinical trials have been conducted to evaluate the safety and efficacy of trabectedin in various cancers. These studies have helped establish its role in treating specific soft tissue sarcomas [1]. Further research may continue to explore its potential in other oncological indications.
What is the regulatory status of Trili?
Trili has received approval from regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses [1].
How does Trili compare to other sarcoma treatments?
Trili is considered an important treatment option for patients with advanced liposarcoma and leiomyosarcoma who have not responded to or cannot tolerate standard chemotherapy, such as anthracyclines [1]. Its mechanism of action is distinct from many other chemotherapy agents, offering an alternative for certain patient populations.
What is the patent situation for Trili?
Information regarding specific patent exclusivity for Trili can be found through resources that track pharmaceutical patents. DrugPatentWatch.com provides data on drug patents, which can indicate when patent protection is set to expire [2]. For detailed patent information on trabectedin, one would typically consult specialized patent databases.
---
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com